Nemacol-1 is a small molecule inhibitor of C. elegans vesicular acetylcholine transporter (VAChT), demonstrates nematode-selective activity (C. elegans, EC50=7.1 uM).

MMV396797 is a small molecule inhibitor of the parasite's phosphatidylinositol kinase PfPI4KIIIB, block parasite protein secretion and export.

MMV019266 is a potent antibabesial inhibitor with IC50 of 0.278 uM and 0.909 uM for Babesia spp. (B. bovis and B. divergens), respectively.

ML304 (ML 304) is a potent, selective inhibitor of Plasmodium falciparum glucose-6-phosphate dehydrogenase (PfG6PDH) with IC50 of 190 nM, with no activity against human G6PD (IC50=80 uM).

ML276 (ML 276) is a potent, selective inhibitor of Plasmodium falciparum glucose-6-phosphate dehydrogenase (PfG6PDH) with IC50 of 889 nM, with no activity against human G6PD.

MBX-4055 is a potent and specific antimalarial compound with IC50 of 42 nM (P. falciparum growth inhibition), acts directly on plasmodial surface anion channel (PSAC, Target K0.5=21 nM) to quantitatively abolish parasite-induced permeability changes.

MBX-2366 (ISG-21) is a potent and specific antimalarial compound with IC50 of 3 nM (P. falciparum growth inhibition), acts directly on plasmodial surface anion channel (PSAC, Target K0.5=2 nM) to quantitatively abolish parasite-induced permeability change

KNX-115 (KNX115) is a potent, selective inhibitor of plasmodium falciparum myosin A (PfMyoA), inhibits PfMyoA actin-activated ATPase with Ki of 17 nM, >50-fold selectivity against cardiac, skeletal, and smooth muscle myosins.

KNX-002 (KNX002) is a potent, specific inhibitor of Toxoplasma gondii class XIV myosin TgMyoA, inhibits TgMyoA ATPase activity with IC50 of 2.8 uM, shows little to no effect on any of the vertebrate myosins.

Halofuginol (MAZ1805) is a halofuginone analog targeting the Plasmodium falciparum prolyl-tRNA synthetase (PfcPRS, Ki=71.1 nM), is highly active against both liver and asexual blood stages of the malaria parasite (EC50=5.8 nM, P. falciparum 3D7 parasite s

Genz-667348 (Genz667348) is a potent, selective P. falciparum DHODH inhibitor with IC50 of 22, 14 and 42 nM for PfDHODH, PbDHODH and PvDHODH, respectively.

ELQ-331 (ELQ331) is an alkoxycarbonate prodrug of antimalarial compound ELQ-300 (P. falciparum cytochrome bc1 complex inhibitor), shows P. falciparum IC50 of 6 nM.

DSM186 (DSM 186) is a high potent A. baumannii DHODH (AbDHODH) inhibitor with IC50 of 28 nM, has MIC <1 ug/mL against geographically diverse A. baumannii strains, including meropenem-resistant isolates.

DSM161 (DSM 161) is a high potent A. baumannii DHODH (AbDHODH) inhibitor, has MIC <1 ug/mL against geographically diverse A. baumannii strains, including meropenem-resistant isolates.

DNDI-6174 is a highly potent inhibitor of Leishmania cytochrome bc1 complex activity, shows broad activity against a panel of representative visceral leishmaniasis clinical isolates from various sources (EC50=10-360 nM).

CWHM-117 is potent nanomolar inhibitor of the Plasmodium aspartic proteases PM-II and PM-IV with IC50 of 4 and 15 nM respectively, exhibits IC50 of 463 nM in the Pf 3D7 infected RBC assays.

AWE402 (AWE-402) is a small molecule inhibitor targeting M. tuberculosis cytochrome bcc-aa3 of the electron transport chain (ETC), shows MIC value of 5 nM activity against Mycobacterium tuberculosis H37Rv.

KAI407 is a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro.

DSM265 is a PfDHODH inhibitor with an IC50 of 8.9 nM. DSM265 can also inhibit the growth of P. falciparum 3D7 parasites with an EC50 of 4.3 nM.

ACT-451840 is an orally active, potent and low-toxicity compound, showing activity against sensitive and resistant plasmodium falciparum strains. ACT-451840 targets all asexual blood stages of the parasite, has a rapid onset of action. ACT-451840 behaves in a way similar to artemisinin derivatives, with very rapid onset of action and elimination of parasite. ACT-451840 can be used for the research of malarial.

INE963 (INE-963) is a potent and fast-acting blood-stage antimalarial, demonstrates potent cellular activity against Pf 3D7 with EC50 of 6 nM in Pf growth inhibition assay.

MMV030084 (MMV-030084) is a potent, specific P. falciparum cGMP-dependent protein kinase (PKG) inhibitor (Kdapp=9-16 nM), inhibits invasion of P. berghei ANKA parasites into HepG2 liver cells with IC50 of 199 nM.MMV030084 potently inhibits hepatocyte invasion by Plasmodium sporozoites, merozoite egress from asexual blood stage schizonts, and male gamete exflagellation, shows potent activity against liver, asexual, and sexual blood stage development.MMV030084 showed an IC50 of 109 nM against the drug-sensitive 3D7-A10 line, and an IC50 of 120 nM against multidrug-resistant Dd2-B2 parasites in a 72-h growth inhibition assay against Pf ABS parasites.MMV030084 inhibited male gamete exflagellation at an IC50 of 141 nM when gametocytes were stimulated to develop into male gametes.MMV030084 is a promising Plasmodium PKG-targeting chemotype.

GSK 3186899 (GSK-3186899, DDD853651) is a novel specific inhibitor of parasite cdc-2-related kinase 12 (CRK12), shows activity against L. donovani in intra-macrophage assay with EC50 value of 1.4 uM, and shows good selectivity against mammalian THP-1 host cells (EC50> 50 uM).

Parabulin is a novel potent, parasite-specific tubulin inhibitor, inhibits growth of parasites while displaying no effects on human cells.

GSK3494245 (DDD01305143) is a potent, orally active, and selective inhibitor of the chymotrypsin-like activity of the parasite proteasome binding in a site sandwiched between the β4 and β5 subunits (IC50=0.16 μM for WT L. donovani proteasomes). GSK3494245 moderately inhibits chymotrypsin-like activity of human proteasome (IC50: purified 26S=13 µM; enriched THP-1 extracts IC50=40µM). GSK3494245 exhibits attractive biological and biosafety properties.

UCB7362 is an orally active and potent antimalarial plasmepsin X (PMX) inhibitor, with an IC50 of 7 nM. UCB7362 inhibits parasite growth.

PF 1022A is a N-methylated cyclooctadepsipeptides (CODPs) with strong anthelmintic properties; acts as an ionophore.

NSC5844 (RE640) is a bisquinoline compound with C-C chemokine receptor type 1 (CCR1)-agonistic properties.

WM382 is an orally active and potent dual plasmepsin IX/X (PMIX/X) inhibitor with IC50 values of 1.4 nM and 0.03 nM, respectively. WM382 has robust in vivo efficacy at multiple stages of the malaria parasite life cycle and an excellent resistance profile.

Bulaquine (CDRI 80/53) is a potent antimalarial agent which is an analogue of Primaquine. Bulaquine affects multiple metabolism pathways and shows inhibition effect on Plasmodium cynomolgi infection. Bulaquine can be used for the research of malaria.